Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma


Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor, chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL).

Currently, CAR T-cell therapies have FDA indications in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), as well as mantle cell lymphoma (MCL). However, this treatment modality is being evaluated for use in several subtypes of NHL in ongoing clinical trials, Vose says. 

For example, trials are investigating CAR T-cell therapy in follicular lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Additionally, other products beyond those FDA approved are being tested in DLBCL and MCL, Vose concludes.

Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Haeseong Park, MD, MPH
Matthew P. Goetz, MD
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center